IGF-1
Increase · moderate
GHRH analog
Literature evidence
Compound library
Vivy evidence dossier
Tesamorelin
Also indexed as Egrifta, Tesamorelin
T1Peptides
Read this entry as context, not instruction.
Evidence labels describe the material available in this reference entry. They do not establish that a compound is appropriate, effective, or safe for you. Inclusion is not a recommendation to use it.
Reference context
Pharmacokinetic context
Half-life4 hr
This field summarizes the library record. Half-life can vary with formulation, indication, and individual clinical context.
Observed relationships
Biomarker context
Waist circumference
Decrease · small
Reduces visceral fat
Literature evidence
Growth hormone
Increase · large
Stimulates pituitary GH release
Literature evidence
IGFBP-3
Increase · moderate
GH-mediated binding proteins
Literature evidence
Fasting glucose
Decrease · moderate
Improves insulin sensitivity
Literature evidence
HbA1c
Decrease · small
Improves glycemic control
Literature evidence
Fasting insulin
Decrease · moderate
Reduces insulin resistance
Literature evidence
HOMA-IR
Decrease · moderate
Improves insulin sensitivity
Literature evidence
Triglycerides
Decrease · small
Improves lipid metabolism
Literature evidence
HDL cholesterol
Increase · small
Improves lipid profile
Literature evidence
Keep in view
Safety discussion points
Tesamorelin is a synthetic GHRH analog approved by FDA for HIV-associated lipodystrophy. Promotes GH and IGF-1 secretion.
Keep the reference close
Track Tesamorelin in context.
Hey Vivy helps you organize protocols and review change over time. It does not diagnose, prescribe, or replace qualified care.